Tiankang Biology: Announcement of Resolutions of the 22nd (Interim) Meeting of the Eighth Board of Directors
Tiankang Biology: Announcement of Resolutions of the 14th (Interim) Meeting of the Eighth Board of Supervisors
Tiankang Biotech: An indicative announcement regarding the holding subsidiary\'s intention to apply for a public offering of shares to unspecified qualified investors and listing on the Beijing Stock Exchange
Tiankang Biotech: Notice on Convening the 6th Extraordinary General Meeting of Shareholders in 2024
Tiankang Biotech: Announcement on the progress of the controlling shareholder increasing the company\'s shares for the first time
Tiankang Biology: Briefing on pig sales in November 2024
Tiankang Biotech: Announcement on the controlling shareholder\'s plan to increase the company\'s share holdings and receiving loan support to increase capital holdings
Tiankang Biology: Announcement on the return of idle funds raised to temporarily supplement working capital
Tiankang Biology: Briefing on pig sales in October 2024
Tiankang Biotech: Announcement on the progress of capital increase to wholly-owned subsidiaries through debt-for-equity swaps
Tiankang Biotech: 002100 Tiankang Biotech Investor Relations Management Information 20241029
Tiankang Biology: Report for the third quarter of 2024
Tiankang Biology: Legal Opinion on the 5th Extraordinary General Meeting of Shareholders of Tiankang Biotech Co., Ltd. in 2024
Tiankang Biotech: Announcement of Resolutions of the Fifth Extraordinary General Meeting of Shareholders in 2024
Tiankang Biology: Briefing on pig sales in September 2024
Tiankang Biology: Announcement on the change of accounting firm
Tiankang Biotech: Notice on Convening the Fifth Extraordinary General Meeting of Shareholders in 2024
Tiankang Biology: Announcement of Resolutions of the 20th (Interim) Meeting of the Eighth Board of Directors
Tiankang Biology: Announcement of Resolutions of the 12th (Interim) Meeting of the Eighth Board of Supervisors
Tiankang Biotech: Announcement on capital increase to wholly-owned subsidiaries through debt-for-equity swaps
No Data